Teva in talks to buy Allergan's generics unit - MarketWatch
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Israeli stocks rise; Brainsway, Ratio Oil off - MarketWatch
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Israel stocks up; FTC eyes Teva-Cephalon deal - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva Pharmaceutical Industries (TEVA) Stock Price, News & Info | The Motley Fool
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Teva Pharmaceuticals stock falls 11% after earnings miss - MarketWatch
Israel stocks at record; Biogen remarks cost Teva - MarketWatch
Israel stocks ease; Teva loses patent ruling - MarketWatch
Three health-care deals today are paying huge premiums - MarketWatch
Teva to buy Allergan generics for $40.5 billion - MarketWatch
Israel stocks fall for fifth day; Teva rises - MarketWatch
Leaner, More Agile Teva Sees Brighter Days Ahead
Teva Pharmaceutical Industries Stock Gives Every Indication Of Being Modestly Undervalued
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva Pharmaceuticals - Wikipedia
Teva appoints Dipankar Bhattacharjee as Prez, CEO Global Generic Group - The Economic Times
